Rock_Robster wrote:[quote=“Amarie123”]Rock_Robster wrote:Hi amarie, it is likely your microsatellite stability status on the report (presume MSS) which precludes you from the currently-approved immunotherapies (PD1 inhibitors), rather than the KRAS mutation. However you may still respond to a PD1 inhibitor if you have a high tumour mutation burden (TMB), or if it’s combined with another drug. There are also lots of immunotherapies beyond PD1 inhibitors presently available through trials. Personally I would be very interested in my TMB status and accessing immuno options for MSS patients, esp. given 5FU-based therapy is off the table.
Also Avastin isn’t usually considered an immunotherapy, rather it’s a targeted therapy known as a monoclonal antibody.
Best of luck,
Thanks for the clarification, it’s a lot of information that I don’t always get right. One issue with some of the treatments is insurance - I might not even be covered for the Avastin if I take it with Lonsurf. My onc is generally on the lookout for clinical trials in the Boston area that I’d be a candidate for.
That’s a pain about the Avastin - I hadn’t heard that about insurance issues when combining with Lonsurf.
Good that your onc is considering local trials - you might also want to look into NIH trials as they also usually cover travel and accommodation expenses, I believe?
Best of luck